VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

Phase 2RecruitingNCT07831369

Inova Health Care Services52 enrolled

Overview

The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas

This is a prospective clinical trial in two cohorts of patients, adults with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas. The study evaluates the efficacy of valproic acid, irinotecan, and simvastatin in recurrent glioma by measuring response rate. The study treatment is as follow: Study Treatment * 21-day cycles * D1 VPA 40mg/kg/dose PO BID and simvastatin at 40mg PO daily * D2 VPA 40mg/kg/dose PO BID, simvastatin at 40mg PO daily, and irinotecan 180mg/m2 IV * D3-21 Continuous simvastatin starting at 40mg daily PO

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Glioblastoma Astrocytoma, IDH-Mutant, Grade 4

Interventions

Valproic Acid (VPA)DRUG

Day 1 40mg/kg/dose PO BID and simvastatin at 40mg PO daily

IrinotecanDRUG

D2 irinotecan 180mg/m2 IV and VPA 40mg/kg/dose PO BID, simvastatin at 40mg PO daily

SimvastatinDRUG

Day3-21 Continuous simvastatin starting at 40mg daily PO

Eligibility

Sex: ALLMin age: 18 YearsMax age: 98 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of glioblastoma or IDH-mutated glioma by WHO 2021 classification * For glioblastoma, at least one prior treatment, which needs to include temozolomide and/or radiation * For IDH-mutated glioma, prior treatment with both radiation and alkylating chemotherapy * Evidence of progression by RANO 2.0 criteria on MRI within last four weeks * At least 1 enhancing measurable lesion Exclusion Criteria: * Use of an enzyme-inducing antiepileptic or other strong inducer of CYP3A4 * Prior treatment with irinotecan * Prior use of valproic acid within 2 months * Anticancer treatment within 4 weeks, 6 weeks if nitrosourea * Active bacterial or fungal infection requiring systemic treatment * Pregnancy * Known mitochondrial disease

Locations (1)

Inova Schar Cancer

Fairfax, Virginia, United States

RECRUITING

Outcomes

Primary Outcomes

Assessing Efficacy as Measured By Response Rate Of Valproic acid, Irinotecan, and Simvastatin in Recurrent Glioma

The response is defined as a confirmed complete response (CR) or partial response (PR) defined by RANO 2.0. Response rate will be calculated as the number of observed response (PR or CR) divided by all treated subjects in the arm.

Time frame: through study completion, an average of 6 months from start of treatment

Secondary Outcomes

Assessing Safety and Adverse Event Rates Of Valproic Acid, Irinotecan, And Simvastatin in Recurrent Glioma

Adverse events will be reported for all patients who receive at least one dose of study medicine.

Time frame: through end of study, average 9 months from start of treatment

Central Contacts

Keary Jane't

CONTACT

(571) 472-3173 keary.jane't@inova.org

Takada Harris

CONTACT

(571) 472-0618 takada.harris@inova.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.